RIPK1 and neoplasm: For instance, RIP kinase 3 (RIPK3) and RIPK1 have been demonstrated to have anti-tumorigenic capacity in CRC (19), although RIPK3-mediated inflammation can induce an immune-suppressive tumor microenvironment (TME), thereby facilitating intestinal tumor progression (19).